secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001356576-24-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q4 rev $164.3M, Qelbree +97% YoY; FY23 GAAP op loss $5.3M, non-GAAP op earnings $125.1M
--------------------------------------------------------------------------------

- Q4 2023 total revenues $164.3M (GAAP); full year 2023 total revenues $607.5M, down 9% YoY.
- Qelbree net sales Q4 $46.4M (+97% YoY), full year $140.2M (+129%); GOCOVRI Q4 $32.0M (+10%), full year $119.6M (+15%).
- Full year 2023 GAAP operating loss $(5.3)M; non-GAAP operating earnings $125.1M. GAAP net earnings $1.3M ($0.02 diluted EPS).
- FY2024 guidance: total revenues $580-$620M; non-GAAP operating earnings $80-$110M; expects generic erosion of Trokendi XR/Oxtellar XR from Sep 2024.
- Pipeline: SPN-830 PDUFA April 5, 2024; Phase IIb SPN-820 data H1 2025; interim Phase IIa SPN-817 data May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/supn-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer